You are here
Broker's take: DBS upgrades Riverstone to 'buy' as valuation turns attractive
DBS Group Research has upgraded Riverstone Holdings to "buy" from "hold" and lowered its target price to S$1.85 from S$2.03.
This comes as the Malaysian glove marker's valuation becomes attractive again after share price correction on vaccine news, DBS said in a research note on Monday.
DBS analyst Ling Lee Keng said Riverstone is now trading at an attractive fiscal 2021 price-to-earnings (PE) ratio of 7.3 times, near the minus-one standard deviation of its five-year PE average.
"Furthermore, we also expect a bumper dividend for FY2020," she added.
The research team expects a firm average selling price on the back of strong demand and tight supply. Order visibility has been further extended to December 2021.
Even with the Covid-19 vaccine's availability, demand is not expected to taper off immediately as hygiene is still a key concern, Ms Ling said. Moreover, the mass availability of vaccines will take time, and the new Covid-19 strain raises risk.
Shares of mainboard-listed Riverstone were trading S$0.02 or 1.5 per cent lower at S$1.33 as at 10.16am on Monday.